pyrazines has been researched along with Liver Neoplasms in 75 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.67) | 18.7374 |
| 1990's | 12 (16.00) | 18.2507 |
| 2000's | 23 (30.67) | 29.6817 |
| 2010's | 34 (45.33) | 24.3611 |
| 2020's | 4 (5.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kanda, Y; Miyazaki, T; Mori, Y; Ochiai, A; Ohata, H; Okamoto, K; Owa, T; Sakai, H; Shiokawa, D; Yokoi, A | 1 |
| Ishida, T; Miyauchi, Y; Sawai, M; Takechi, S | 1 |
| Deng, B; Fang, Z; He, Y; Huang, K; Li, J; Liu, S; Ning, Y; Pan, X; Xu, X; Yang, Z | 1 |
| Cui, X; Dong, K; Du, Q; Geller, DA; Guo, Y; Yan, Y; Zheng, L | 1 |
| Chen, D; Liu, M; Qiu, C; Sun, K; Wang, J; Xie, Z | 1 |
| Chen, D; Fan, F; Liu, Q; Shi, Y; Tian, D | 1 |
| Fu, X; Guo, H; Li, CL; Lu, J; Nan, KJ; Tian, T; Wang, SH; Yang, YJ; Yao, Y | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Afify, HG; Attia, MS; El-Kemary, M; Elsaady, MM; Hashem, SG; Omer, WE; Youssef, AO | 1 |
| Afjei, R; Citterio, D; Hiruta, Y; Iwasawa, N; Kim, SB; Nakajima, T; Natarajan, A; Nishihara, R; Nishiyama, S; Paulmurugan, R; Sato, M; Suzuki, K; Yamamoto, E | 1 |
| Chen, KF; Hou, DR; Huang, AC; Shiau, CW; Wang, CY; Yu, HC | 1 |
| Baiz, D; Chiaretti, S; Consoloni, L; Dapas, B; Farra, R; Fiotti, N; Grassi, G; Pozzato, G; Scaggiante, B; Zanconati, F | 1 |
| Hong, SY; Kang, S; Min, J; Moon, H; Shin, HH; Yang, HJ | 1 |
| Amiri, KI; Benson, AB; Berlin, J; Ciombor, KK; Feng, Y; Horton, L; Kauh, JS; Mulcahy, M; Powell, M; Richmond, A; Short, SP; Staley, C; Su, Y | 1 |
| Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P | 1 |
| Cai, J; Chen, YJ; Huang, L; Liu, A; Ouyang, Y; Tu, Q; Wang, Y; Xiao, D; Yan, W; Zeng, X; Zeng, Z | 1 |
| Bi, L; Cao, J; Miao, Q; Miao, S; Wang, S; Xie, Y; Yang, Q; Zhang, J; Zhang, M; Zhang, S; Zhou, X | 1 |
| Jiang, J; Liu, J; Wang, Y; Wu, X; Xu, J; Xu, S; Yao, H; Ye, W; Zhang, H; Zhu, P | 1 |
| Auriemma, RS; Colao, A; Cuomo, G; de Angelis, C; De Martino, MC; Hofland, LJ; Izzo, F; Napolitano, M; Negri, M; Pivonello, C; Pivonello, R; Provvisiero, DP; Simeoli, C | 1 |
| Bi, L; Chen, W; Gao, J; Qian, L; Qiu, S; Yan, X | 1 |
| Armeanu, S; Baltz, KM; Bitzer, M; Krusch, M; Lauer, UM; Salih, HR; Smirnow, I; Steinle, A; Weiss, TS | 1 |
| Chen, KF; Cheng, AL; Huang, SY; Lu, YS; Yeh, KH; Yeh, PY | 1 |
| Kim, SG; Shin, SM | 1 |
| Baiz, D; Dapas, B; Farra, R; Giansante, C; Grassi, G; Grassi, M; Guarnieri, G; Pozzato, G; Scaggiante, B; Uxa, L; Zennaro, C | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Hsieh, HP; Hsu, C; Hsu, CH; Lu, YS; Yeh, PY | 1 |
| Guillouzo, A; Langouet, S; Morel, F; Piton, A; Rauch, C | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC | 1 |
| Guo, LY; Li, HL; Liu, M; Liu, Y; Wang, JN; Wang, SS; Wang, XB; Xiang, JZ; Zhang, QF; Zheng, F | 1 |
| Dhanasekaran, DN; Ha, JH; Jayaraman, M; Kim, SG; Kwak, MK; Lee, CH; Lee, S; Nam, CW; Yang, YM | 1 |
| Boozari, B; Gürlevik, E; Kloos, A; Knocke, S; Kubicka, S; Kühnel, F; Manns, MP; Mundt, B; Schache, P; Strüver, N; Wirth, TC; Woller, N | 1 |
| Boyer, M; Erlichman, C; Holen, K; Kim, GP; Mahoney, MR; Marshke, R; Mok, TS; Nowak, A; Philip, PA; Picus, J; Pitot, HC; Rubin, J; Szydlo, D; Wright, JJ | 1 |
| Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M | 1 |
| Chen, HJ; Chen, KF; Chen, PJ; Chen, YC; Cheng, AL; Hou, DR; Liu, CY; Yu, HC | 1 |
| Eckhardt, SG; Kulikowski, GN; Morelli, MP; Pitts, TM; Serkova, NJ; Spratlin, JL; Tentler, JJ | 1 |
| Buck, E; Desai, V; Epstein, DM; Miglarese, M; Wang, J; Zhao, H | 1 |
| Gao, D; Guo, K; Jiang, K; Jin, G; Kang, X; Li, Y; Liu, Y; Shu, H; Sun, C; Sun, H; Sun, L; Wang, C; Wu, W | 1 |
| Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS | 1 |
| Banerjee, A; Gartel, AL; Halasi, M; Kabirov, K; Landolfi, J; Lyubimov, AV; Wang, M | 1 |
| Chang, TC; Chen, SC; Jan, YJ; Ko, BS; Liang, SM; Liou, JY; Liu, TA; Wang, J; Wu, YM | 1 |
| Bantel, H; Kontermann, R; Krech, T; Länger, F; Lehner, F; Manns, MP; Nüssler, A; Pfizenmaier, K; Schulze-Osthoff, K; Siegemund, M; Vondran, F; Wahl, K | 1 |
| Fujisawa, K; Hirose, Y; Matsumoto, T; Murata, Y; Saeki, I; Sakaida, I; Takami, T; Terai, S; Yamamoto, N; Yamasaki, T | 1 |
| Ishida, T; Takechi, S; Yamaguchi, T | 1 |
| Chen, KF; Cheng, AL; Hou, DR; Lin, CS; Liu, CY; Shiau, CW; Yu, HC | 1 |
| Egner, PA; Gange, SJ; Groopman, JD; Jacobson, LP; Kensler, TW; Kuang, SY; Muñoz, A; Qian, GS; Wang, JB; Zhang, BC; Zhu, YR | 1 |
| Gong, JP; Li, XH; Liu, CA; Mei, Y; Ren, MJ; Shi, YJ; Zuo, GQ | 1 |
| Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P | 1 |
| Chu, H; Kensler, TW; Muñoz, A | 1 |
| Ganten, TM; Haas, TL; Herzer, K; Koschny, R; Li-Weber, M; Sykora, J; Walczak, H | 1 |
| Calvaruso, G; Carlisi, D; D'Anneo, A; Emanuele, S; Lauricella, M; Portanova, P; Tesoriere, G; Vassallo, B; Vento, R | 1 |
| Hu, Z; Lin, LN; Wang, WT; Wu, JZ; Xie, K | 1 |
| Arnold, AC; Back, TC; Hixon, JA; Khan, T; Lincoln, E; Lockett, S; Powell, D; Salcedo, R; Sayers, TJ; Stauffer, JK; Wigginton, JM; Williams, R | 1 |
| Calvaruso, G; De Blasio, A; Giuliano, M; Portanova, P; Tesoriere, G; Vento, R | 1 |
| Glintborg, B; Kensler, TW; Poulsen, HE; Weimann, A | 1 |
| Calvaruso, G; Giuliano, M; Pellerito, O; Portanova, P; Tesoriere, G; Vento, R | 1 |
| Kensler, TW; Yates, MS | 1 |
| Ito, S; Katoh, T; Omori, H; Takechi, S; Takeda, O; Yamaguchi, T | 1 |
| Nawasreh, M | 1 |
| Corral, J; de Arriba, F; Ferrer, F; González, M; Hernández-Espinosa, D; Martínez, C; Miñano, A; Mota, RA; Ordoñez, A; Pérez-Ceballos, E; Vicente, V | 1 |
| Sato, N; Uehara, M | 1 |
| Helzlsouer, KJ; Kensler, TW | 1 |
| Buiatti, E | 1 |
| Groopman, JD; Kensler, TW | 1 |
| Chen, B; Davidson, NE; Egner, PA; Enger, C; Fang, X; Gordon, GB; Gorman, MB; Groopman, JD; Helzlsouer, KJ; Jacobson, LP; Kensler, TW; Kuang, SY; Li, YF; Muñoz, A; Prochaska, HJ; Qian, GS; Wang, JB; Wu, Y; Yu, LY; Zarba, A; Zhang, BC; Zhang, QN; Zhu, YR | 1 |
| Kensler, TW | 1 |
| Chen, B; Davidson, NE; Egner, PA; Enger, C; Fang, X; Gordon, GB; Gorman, MB; He, X; Helzlsouer, KJ; Jacobson, LP; Kensler, TW; Kuang, SY; Li, YF; Muñoz, A; Otieno, M; Prochaska, HJ; Qian, GS; Wang, JB; Wang, JS; Wu, Y; Yu, LY; Zarba, A; Zhang, BC; Zhang, QN; Zhu, YR | 1 |
| Ansari, RH; Brockstein, BE; Garcia, JC; Mani, S; Meyer, SC; Mick, R; Ratain, MJ; Rhinehart, SN; Schilsky, RL; Stadler, WM; Taber, D; Vogelzang, NJ; Vokes, EE | 1 |
| Chen, B; Davidson, NE; De Flora, S; Egner, PA; Enger, CL; Fang, X; Gordon, GB; Gorman, MB; Groopman, JD; He, X; Jacobson, LP; Kensler, TW; Kuang, SY; Li, YF; Muñoz, A; Prochaska, HJ; Qian, GS; Wang, JB; Wang, JS; Wu, Y; Yu, LY; Zarba, A; Zhang, BC; Zhang, QN; Zhu, YR | 1 |
| Kato, A; Kubo, K; Matsuzaki, Y; Okita, K; Terai, S | 1 |
| Egner, PA; Groopman, JD; He, X; Helzlsouer, KJ; Jacobson, LP; Kensler, TW; Kuang, SY; Muñoz, A; Qian, GS; Shen, X; Wang, JB; Wang, JS; Zarba, A; Zhang, BC; Zhu, YR | 1 |
| Groopman, JD; Jackson, PE | 1 |
| Egner, PA; Groopman, JD; Kensler, TW; Li, Y; Qin, L; Roebuck, BD; Su, J; Wang, J | 1 |
| Dolan, PM; Egner, PA; Groopman, JD; Itoh, K; Kensler, TW; Kwak, MK; Ramos-Gomez, M; Yamamoto, M | 1 |
| Cadet, J; Di Mascio, P; Dörnemann, D; Douki, T; Medeiros, MH; Onuki, J; Teixeira, PC | 1 |
| Epstein, SS; Mantel, N | 1 |
| Reynolds, TB; Yamada, S | 1 |
9 review(s) available for pyrazines and Liver Neoplasms
| Article | Year |
|---|---|
Strategies for chemoprevention of liver cancer.
Topics: Anticarcinogenic Agents; Carcinoma, Hepatocellular; Chemoprevention; Chlorophyllides; Clinical Trials as Topic; Female; Forecasting; Humans; Liver Neoplasms; Male; Primary Prevention; Prognosis; Pyrazines; Risk Assessment; Thiones; Thiophenes | 2002 |
Keap1 eye on the target: chemoprevention of liver cancer.
Topics: Aflatoxins; Animals; Anticarcinogenic Agents; Antioxidants; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Intracellular Signaling Peptides and Proteins; Isothiocyanates; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; NF-E2-Related Factor 2; Phenols; Pyrazines; Signal Transduction; Sulfoxides; Thiocyanates; Thiones; Thiophenes; Triterpenes | 2007 |
Oltipraz: clinical opportunities for cancer chemoprevention. p.
Topics: Animals; Anticarcinogenic Agents; Clinical Trials as Topic; Disease Models, Animal; Evaluation Studies as Topic; Humans; Liver Neoplasms; Pyrazines; Risk Factors; Schistosomicides; Thiones; Thiophenes | 1995 |
Chemoprevention of primary liver cancer.
Topics: Anticarcinogenic Agents; Cancer Vaccines; Carcinoma, Hepatocellular; Chemoprevention; Humans; Liver Neoplasms; Nutritional Physiological Phenomena; Pyrazines; Thiones; Thiophenes | 1996 |
Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials.
Topics: Aflatoxin B1; Aflatoxins; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Carcinogens; Clinical Trials as Topic; Cohort Studies; DNA Adducts; Guanine; Hepatitis B; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Proteins; Pyrazines; Risk Factors; Thiones; Thiophenes | 1996 |
Chemoprevention by inducers of carcinogen detoxication enzymes.
Topics: Aflatoxin B1; Animals; Anticarcinogenic Agents; Enzyme Induction; Humans; Liver Neoplasms; Pyrazines; Rats; Thiones; Thiophenes | 1997 |
Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Disease Models, Animal; Double-Blind Method; Humans; Liver Neoplasms; Placebos; Pyrazines; Rats; Thiones; Thiophenes; Treatment Outcome | 1997 |
Aflatoxin and liver cancer.
Topics: Aflatoxins; Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Environmental Exposure; Genes, p53; Humans; Incidence; Liver Neoplasms; Mutation; Pyrazines; Thiones; Thiophenes | 1999 |
Role of phase 2 enzyme induction in chemoprotection by dithiolethiones.
Topics: Aflatoxin B1; Animals; Antineoplastic Agents; Carcinogens; Chemoprevention; China; Controlled Clinical Trials as Topic; Enzyme Induction; Gene Expression; Glucuronosyltransferase; Glutathione Transferase; Humans; Inactivation, Metabolic; Liver Neoplasms; Pyrazines; Quinone Reductases; Thiones; Thiophenes | 2001 |
13 trial(s) available for pyrazines and Liver Neoplasms
| Article | Year |
|---|---|
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Chemokine CCL5; Cytokines; Disease-Free Survival; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; North America; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome; Young Adult | 2012 |
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis | 2011 |
Assessing the effect of interventions in the context of mixture distributions with detection limits.
Topics: Anticarcinogenic Agents; Biomarkers, Tumor; Carcinogens; Carcinoma, Hepatocellular; China; Double-Blind Method; Humans; Likelihood Functions; Liver Neoplasms; Models, Statistical; Placebos; Pyrazines; Sensitivity and Specificity; Thiones; Thiophenes | 2005 |
[Protective effect of ligustrazine and propofol on peri-operational liver ischemia-reperfusion injury].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Drug Therapy, Combination; Female; Humans; Lipid Peroxides; Liver; Liver Neoplasms; Male; Middle Aged; Propofol; Pyrazines; Reperfusion Injury; Superoxide Dismutase | 2006 |
Oltipraz chemoprevention trial in Qidong, People's Republic of China: unaltered oxidative biomarkers.
Topics: Anticarcinogenic Agents; Biomarkers; Carcinoma, Hepatocellular; China; DNA; Guanine; Humans; Liver Neoplasms; Oxidation-Reduction; Oxidative Stress; Placebos; Pyrazines; Thiones; Thiophenes | 2006 |
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.
Topics: Alleles; alpha 1-Antitrypsin; Animals; Antineoplastic Agents; Antithrombins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Endoplasmic Reticulum; Factor Xa Inhibitors; Fibrinogen; Humans; Immunohistochemistry; Injections, Intravenous; Leukocyte Elastase; Liver; Liver Neoplasms; Male; Mice; Molecular Chaperones; Multiple Myeloma; Proteasome Inhibitors; Proteins; Pyrazines; Serpins; Ubiquitin | 2008 |
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes.
Topics: Adult; Aflatoxins; Aged; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Pyrazines; Thiones; Thiophenes | 1997 |
Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.
Topics: Adult; Aflatoxins; Aged; Albumins; Anticarcinogenic Agents; Biomarkers; Carcinoma, Hepatocellular; China; Dose-Response Relationship, Drug; Genotype; Glutathione Transferase; Humans; Liver Neoplasms; Middle Aged; Pyrazines; Radioimmunoassay; Risk Assessment; Thiones; Thiophenes | 1998 |
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pyrazines; Survival Rate | 1998 |
Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Disease Models, Animal; Double-Blind Method; Humans; Liver Neoplasms; Placebos; Pyrazines; Rats; Thiones; Thiophenes; Treatment Outcome | 1997 |
Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China.
Topics: Acetylcysteine; Aflatoxin B1; Anticarcinogenic Agents; Carcinogens; China; Cytochrome P-450 CYP1A2; Double-Blind Method; Drug Administration Schedule; Feasibility Studies; Gas Chromatography-Mass Spectrometry; Glutathione Transferase; Humans; Liver Neoplasms; Pyrazines; Reproducibility of Results; Thiones; Thiophenes; Treatment Outcome | 1999 |
Amiloride (MK-870), a new antikaluretic diuretic. Comparison to other antikaluretic diuretics in patients with liver disease and ascites.
Topics: Acid-Base Equilibrium; Amidines; Ascites; Autopsy; Carcinoma; Diuretics; Ethacrynic Acid; Humans; Hydrochlorothiazide; Hydrogen-Ion Concentration; Hyperkalemia; Liver Cirrhosis; Liver Neoplasms; Pyrazines; Spironolactone; Triamterene; Water-Electrolyte Balance | 1970 |
54 other study(ies) available for pyrazines and Liver Neoplasms
| Article | Year |
|---|---|
NF-κB suppression synergizes with E7386, an inhibitor of CBP/β-catenin interaction, to block proliferation of patient-derived colon cancer spheroids.
Topics: Adenocarcinoma; beta Catenin; Cell Cycle Checkpoints; Cell Proliferation; Colonic Neoplasms; CREB-Binding Protein; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; NF-kappa B; Phenylenediamines; Primary Cell Culture; Pyrazines; Spheroids, Cellular; Triazines; Wnt Signaling Pathway | 2022 |
Dihydropyrazine suppresses TLR4-dependent inflammatory responses by blocking MAPK signaling in human hepatoma HepG2 cells.
Topics: Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Lipopolysaccharides; Liver Neoplasms; NF-kappa B; Pyrazines; Signal Transduction; Toll-Like Receptor 4 | 2022 |
Piezo1 impairs hepatocellular tumor growth via deregulation of the MAPK-mediated YAP signaling pathway.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Ion Channels; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Signal Transduction; Thiadiazoles; Transcription Factors; Tumor Burden | 2021 |
Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells.
Topics: Animals; Apoptosis; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Female; Hep G2 Cells; Humans; Interferon Regulatory Factor-1; Liver Neoplasms; Mice; MicroRNAs; Neoplasm Transplantation; Phosphorylation; Prognosis; Pyrazines; Pyrazoles; STAT3 Transcription Factor; Up-Regulation | 2021 |
CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
Topics: Aged; Animals; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, SCID; Middle Aged; Mitochondria; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrazines; Reactive Oxygen Species; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
The Wnt inhibitor LGK-974 enhances radiosensitivity of HepG2 cells by modulating Nrf2 signaling.
Topics: Acyltransferases; Apoptosis; Endoplasmic Reticulum; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Proteins; NF-E2-Related Factor 2; Pyrazines; Pyridines; Radiation Tolerance; Reactive Oxygen Species; Signal Transduction; Wnt Signaling Pathway; Wnt3A Protein | 2017 |
β1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway.
Topics: Apoptosis; Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin beta1; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Spheroids, Cellular; Sulfonamides | 2018 |
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1 | 2018 |
Determination of uric acid in serum using an optical sensor based on binuclear Pd(II) 2-pyrazinecarboxamide-bipyridine doped in a sol gel matrix.
Topics: 2,2'-Dipyridyl; Carcinoma, Hepatocellular; Cardiovascular Diseases; Coordination Complexes; Gels; Humans; Liver Neoplasms; Optical Devices; Optical Imaging; Palladium; Pyrazines; Uric Acid | 2019 |
Highly bright and stable NIR-BRET with blue-shifted coelenterazine derivatives for deep-tissue imaging of molecular events
Topics: Amino Acid Sequence; Animals; Binding Sites; Breast Neoplasms; Chlorocebus aethiops; COS Cells; Female; Fluorescence Resonance Energy Transfer; HeLa Cells; Heterografts; Humans; Imidazoles; Liver Neoplasms; Luciferases; Luminescent Agents; Luminescent Measurements; Luminescent Proteins; Lung Neoplasms; Mice; Models, Molecular; Molecular Imaging; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Pyrazines; Receptors, Estrogen; Recombinant Fusion Proteins; Red Fluorescent Protein; Single-Cell Analysis | 2019 |
Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition.
Topics: Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Molecular Structure; Pyrazines; Structure-Activity Relationship | 2013 |
Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Proliferation; Cyclins; E2F Transcription Factors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Phenotype; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Messenger; Transfection | 2014 |
Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Capsid Proteins; Carcinoma, Hepatocellular; Catechols; Drug Delivery Systems; Humans; Liver Neoplasms; Nanocomposites; Pyrazines | 2014 |
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Reactive Oxygen Species; Signal Transduction; src-Family Kinases | 2015 |
CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inflammation; Lipopolysaccharides; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Myeloid Differentiation Factor 88; NF-kappa B; Piperazines; Pyrazines; Toll-Like Receptor 4 | 2015 |
Tetramethylpyrazine (TMP) exerts antitumor effects by inducing apoptosis and autophagy in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Dose-Response Relationship, Drug; Flow Cytometry; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Pyrazines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2015 |
Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; G1 Phase; HeLa Cells; Humans; Liver Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Morpholines; Pyrazines; Structure-Activity Relationship; Triterpenes | 2015 |
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Combinations; Everolimus; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Imidazoles; Insulin; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Sirolimus; TOR Serine-Threonine Kinases | 2016 |
Antihepatocellular Carcinoma Potential of Tetramethylpyrazine Induces Cell Cycle Modulation and Mitochondrial-Dependent Apoptosis: Regulation of p53 Signaling Pathway in HepG2 Cells In Vitro.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytochromes c; G1 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Resting Phase, Cell Cycle; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescent Antibody Technique; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Interferon-gamma; Killer Cells, Natural; Liver Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Cycle; Down-Regulation; Flow Cytometry; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners.
Topics: Apoptosis; Arachidonic Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Formazans; Humans; In Situ Nick-End Labeling; Iron; Liver Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Pyrazines; Reactive Oxygen Species; Tetrazolium Salts; Thiones; Thiophenes; Time Factors | 2009 |
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Topics: Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; E2F1 Transcription Factor; G2 Phase; Humans; Liver Neoplasms; Pyrazines; RNA, Messenger; S Phase; Time Factors | 2009 |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Liver Neoplasms; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes.
Topics: Anticarcinogenic Agents; Aryl Hydrocarbon Hydroxylases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP2B6; Gene Expression Regulation; Hepatocytes; Humans; Hydroxylation; Liver Neoplasms; Oxidoreductases, N-Demethylating; Pregnane X Receptor; Pyrazines; Receptors, Steroid; RNA, Messenger; Testosterone; Thiones; Thiophenes | 2010 |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Plant Extracts; Plant Roots; Pyrazines | 2010 |
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line; GTP-Binding Protein alpha Subunits, G12-G13; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger | 2010 |
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Combined Modality Therapy; Endoplasmic Reticulum; Female; Immunity, Cellular; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2010 |
Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.
Topics: Animals; Antibodies, Neoplasm; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2011 |
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolomics; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sulfonamides | 2011 |
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Topics: Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Insulin-Like Growth Factor II; Liver Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Diethylnitrosamine; Disease Models, Animal; Liver; Liver Neoplasms; Mice; Phenobarbital; Pyrazines; Thiostrepton | 2012 |
Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Survival; Drug Screening Assays, Antitumor; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; NF-kappa B; Pyrazines; Structure-Activity Relationship; Tumor Cells, Cultured; Up-Regulation | 2013 |
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; ErbB Receptors; Hepatocytes; Humans; Liver Neoplasms; Molecular Targeted Therapy; Pyrazines; Recombinant Fusion Proteins; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Death; Liver Cirrhosis; Liver Neoplasms; Male; Pyrazines; Rats; Rats, Wistar | 2013 |
Possible involvement of glutathione balance disruption in dihydropyrazine-induced cytotoxicity on human hepatoma HepG2 cells.
Topics: Carcinoma, Hepatocellular; Cell Survival; Glutathione; Glutathione Disulfide; Hep G2 Cells; Humans; Liver Neoplasms; Pyrazines | 2012 |
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
Topics: Acridine Orange; Autoantigens; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Phosphorylation; Proteasome Endopeptidase Complex; Protein Phosphatase 2; Pyrazines; Time Factors | 2013 |
[Study on ligustrazine in reversing multidrug resistance of HepG2/ADM cell in vitro].
Topics: ATP Binding Cassette Transporter, Subfamily B; Calcium Channel Blockers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytotoxicity, Immunologic; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Glycoproteins; Humans; Liver Neoplasms; Pyrazines | 2004 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Middle Aged; Multiple Myeloma; Plasma Cells; Plasmacytoma; Pyrazines; Recurrence; Thalidomide | 2005 |
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Hepatocytes; Humans; Liver Neoplasms; Membrane Glycoproteins; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Caspases; Cell Line; Cell Line, Tumor; Fas Ligand Protein; Heat-Shock Proteins; Humans; Liver; Liver Neoplasms; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinase 8; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Pyrazines; Signal Transduction; Transcription Factor AP-1; Tumor Necrosis Factors | 2006 |
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytokines; Disease Models, Animal; Growth Inhibitors; Interleukin-12; Interleukin-2; Liver Neoplasms; Male; Mice; Mice, Inbred A; Neuroblastoma; Proteasome Inhibitors; Pyrazines | 2006 |
Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.
Topics: Boronic Acids; Bortezomib; Caspase 8; Cell Line; Cell Line, Tumor; Humans; I-kappa B Proteins; Liver; Liver Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Pyrazines | 2006 |
Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; HSP72 Heat-Shock Proteins; Humans; Immunoprecipitation; Liver Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Suppressor Protein p53 | 2007 |
Effects of phenyl derivatives of dihydropyrazines with ability to generate radical species on Escherichia coli.
Topics: Aminolevulinic Acid; Copper; DNA; DNA Repair; Electron Spin Resonance Spectroscopy; Escherichia coli K12; Liver Neoplasms; Mutation; Phenyl Ethers; Pyrazines; Tetrazolium Salts | 2007 |
Chemo-, regio-, and stereoselectivity of F-ring opening reactions in the cephalostatin series.
Topics: Antineoplastic Agents; Boranes; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Phenazines; Pyrazines; Spiro Compounds; Steroids; Stomach Neoplasms; Structure-Activity Relationship | 2008 |
Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma.
Topics: Alanine Transaminase; Bilirubin; Carcinoma, Hepatocellular; Chronic Disease; Female; Free Radicals; Hepatitis, Chronic; Humans; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Luminescent Measurements; Luminol; Male; Middle Aged; Neutrophils; Oxygen; Prothrombin Time; Pyrazines; Serum Albumin | 1994 |
Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Dose-Response Relationship, Drug; Humans; In Situ Nick-End Labeling; Isoxazoles; Liver Neoplasms; Pyrazines; Quinolines; Tumor Cells, Cultured | 1999 |
Reduction of aflatoxin B(1) adduct biomarkers by oltipraz in the tree shrew (Tupaia belangeri chinensis).
Topics: Aflatoxin B1; Animals; Anticarcinogenic Agents; Antiviral Agents; Biomarkers; Chromatography, High Pressure Liquid; DNA Adducts; Female; Hepatitis B virus; Humans; Liver Neoplasms; Male; Pyrazines; Radioimmunoassay; Thiones; Thiophenes; Time Factors; Tupaiidae | 2000 |
Is 5-aminolevulinic acid involved in the hepatocellular carcinogenesis of acute intermittent porphyria?
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aminolevulinic Acid; Animals; Deoxyguanosine; DNA; DNA Damage; Liver Neoplasms; Metals; Plasmids; Porphyria, Acute Intermittent; Propionates; Pyrazines; Rats; Valerates | 2002 |
Hepatocarcinogenicity of the herbicide maleic hydrazide following parenteral administration to infant Swiss mice.
Topics: Animals; Animals, Newborn; Carcinoma, Hepatocellular; Herbicides; Injections, Subcutaneous; Liver Neoplasms; Maleates; Mice; Pyrazines | 1968 |